Safety and Pharmacology Evaluations : Conducting preclinical toxicology, pharmacokinetic, and receptor-binding studies to characterize how AOD 9604 is handled in vivo and confirm it does not activate growth hormone-like proliferative pathways
I have heard of a connection with lupus though
Second, exogenous IGF-1 can suppress the natural overnight GH pulse through hypothalamic-pituitary feedback
A higher-dose option is also available (10mg BPC-157, 10mg TB-500, 50mg GHK-Cu) for studies requiring increased peptide concentrations
Standard laboratory tools, accurate micro-pipettes, and sterile bacteriostatic water are sufficient for correct reconstitution and measurement
The FDA may eventually pull unsafe peptides after testing and approve others, prompting big pharma to mass-produce a version that they can patent and sell